Jiangsu Hengrui Pharmaceuticals revenue and financials
¥47.20Change from previous close: +3.46%Absolute change: +¥1.58
In the fiscal year ended December 2025, Jiangsu Hengrui Pharmaceuticals reported revenue of ¥31.63B (+13.02% year over year). Net income was ¥7.71B, a net margin of 24.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +13.02%
- 2025 vs 2024
- Net income growth
- +21.69%
- 2025 vs 2024
- Net margin
- 24.4%
- 2024: 22.6%
Financial data
Amounts in millions of CNY; per-share values in CNY; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Capital expenditure | -873 | -705 | -1,247 | -566 | -702 |
| Investing cash flow | -1,101 | -724 | -1,214 | -553 | -532 |
| Financing cash flow | -1,404 | -186 | -309 | 8,701 | -661 |
| Dividends paid | — | — | -10.1 | — | — |
| Debt issued | 1,192 | 300 | 1,067 | — | — |
| Debt repaid | -1,193 | -300 | — | — | — |
| Effect of exchange rates | -347 | -350 | -214 | 18.7 | 29.6 |
| Net change in cash | -1,304 | -123 | 601 | 11,893 | -638 |
| Free cash flow | 328 | 81.6 | 878 | 3,180 | -147 |